USADA joined forces with the International Association of Athletics Federations (IAAF) to conduct outreach education efforts at the IAAF Junior World Championships held in July at the fabled Hayward Field on the University of Oregon’s campus in Eugene, Oregon.
As a member of the Endocrine Society’s Scientific Task Force (SSTF), USADA’s Chief Science Officer, Dr. Larry Bowers, was an author of the scientific statement, “Adverse Health Consequences of Performance-Enhancing Drugs,” published in the Endocrine Society journal, Endocrine Reviews.
Inhalation of volumes of concentrated gases such as carbon monoxide, hydrogen sulfide, and xenon, even with medical supervision, may carry serious health risks.
IGF-1 can enhance the production of lean muscle as well as aid in recovery time, but when used without medical necessity, exogenous IGF-1 can cause serious harm.
We have seen an increase in inquires at USADA about the use of Intravenous (IV) Infusions for this purpose, and would like to assist athletes and medical personnel by clarifying this.
What’s the difference between autologous, homologous (allogenic), and heterologous blood transfusions?
Autologous blood transfusion is the collection and re-infusion of the patient’s own blood or blood components.
USADA must collect a minimum of 90mL during a urine test to ensure that all drug tests can be performed.